Precision BioSciences
Patents, Design & Utilities

Last updated:

List of all Precision BioSciences patents 64 in total

Status Patent
Application
Utility: LYMPHODEPLETION DOSING REGIMENS FOR CELLULAR IMMUNOTHERAPIES External link
Filling date: 8 Sep 2025 Issue date: 1 Sep 2022
Application
Utility: COMPOSITIONS AND METHODS FOR SEQUENTIAL STACKING OF NUCLEIC ACID SEQUENCES INTO A GENOMIC LOCUS External link
Filling date: 8 Sep 2025 Issue date: 1 Sep 2022
Application
Utility: ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE HEPATITIS B VIRUS GENOME External link
Filling date: 8 Sep 2025 Issue date: 4 Aug 2022
Application
Utility: NUCLEIC ACID MOLECULES ENCODING AN ENGINEERED ANTIGEN RECEPTOR AND AN INHIBITORY NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOF External link
Filling date: 8 Sep 2025 Issue date: 21 Jul 2022
Grant
Utility: Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) External link
Filling date: 8 Sep 2025 Issue date: 12 Jul 2022
Application
Utility: METHODS OF PREPARING POPULATIONS OF GENETICALLY-MODIFIED IMMUNE CELLS External link
Filling date: 8 Sep 2025 Issue date: 30 Jun 2022
Application
Utility: ENGINEERED NUCLEASES USEFUL FOR TREATMENT OF HEMOPHILIA A External link
Filling date: 8 Sep 2025 Issue date: 23 Jun 2022
Application
Utility: OPTIMIZATION OF ENGINEERED MEGANUCLEASES FOR RECOGNITION SEQUENCES External link
Filling date: 8 Sep 2025 Issue date: 23 Jun 2022
Application
Utility: NUCLEIC ACIDS ENCODING ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE External link
Filling date: 8 Sep 2025 Issue date: 19 May 2022
Application
Utility: TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES External link
Filling date: 8 Sep 2025 Issue date: 12 May 2022
Application
Utility: GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE External link
Filling date: 8 Sep 2025 Issue date: 12 May 2022
Application
Utility: GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE External link
Filling date: 8 Sep 2025 Issue date: 5 May 2022
Application
Utility: GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED TRANSFERRIN GENE External link
Filling date: 8 Sep 2025 Issue date: 21 Apr 2022
Grant
Utility: Co-stimulatory domains for use in genetically-modified cells External link
Filling date: 8 Sep 2025 Issue date: 29 Mar 2022
Application
Utility: GENETIC MODIFICATION OF THE HYDROXYACID OXIDASE 1 GENE FOR TREATMENT OF PRIMARY HYPEROXALURIA External link
Filling date: 8 Sep 2025 Issue date: 24 Mar 2022
Grant
Utility: Engineered nucleases useful for treatment of hemophilia A External link
Filling date: 8 Sep 2025 Issue date: 22 Mar 2022
Grant
Utility: Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome External link
Filling date: 8 Sep 2025 Issue date: 15 Mar 2022
Grant
Utility: Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene External link
Filling date: 8 Sep 2025 Issue date: 8 Mar 2022
Grant
Utility: Nucleic acids encoding engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene External link
Filling date: 8 Sep 2025 Issue date: 8 Mar 2022
Application
Utility: OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME External link
Filling date: 8 Sep 2025 Issue date: 24 Feb 2022
Application
Utility: GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR) External link
Filling date: 8 Sep 2025 Issue date: 10 Feb 2022
Grant
Utility: Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) External link
Filling date: 8 Sep 2025 Issue date: 30 Nov 2021
Grant
Utility: Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome External link
Filling date: 8 Sep 2025 Issue date: 12 Oct 2021
Application
Utility: GENETICALLY-MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE T CELL RECEPTOR ALPHA GENE External link
Filling date: 8 Sep 2025 Issue date: 9 Sep 2021
Application
Utility: GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR) External link
Filling date: 8 Sep 2025 Issue date: 19 Aug 2021
Application
Utility: PRECISE DELETION OF CHROMOSOMAL SEQUENCES IN VIVO AND TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS USING ENGINEERED NUCLEASES External link
Filling date: 8 Sep 2025 Issue date: 29 Jul 2021
Application
Utility: GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE External link
Filling date: 8 Sep 2025 Issue date: 8 Jul 2021
Grant
Utility: Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene External link
Filling date: 8 Sep 2025 Issue date: 6 Jul 2021
Application
Utility: ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE HEPATITIS B VIRUS GENOME External link
Filling date: 8 Sep 2025 Issue date: 17 Jun 2021
Application
Utility: DYSTROPHIN GENE EXON DELETION USING ENGINEERED NUCLEASES External link
Filling date: 8 Sep 2025 Issue date: 20 May 2021
Grant
Utility: Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) External link
Filling date: 8 Sep 2025 Issue date: 18 May 2021
Application
Utility: RECOGNITION SEQUENCES FOR I-CREI-DERIVED MEGANUCLEASES AND USES THEREOF External link
Filling date: 8 Sep 2025 Issue date: 6 May 2021
Application
Utility: OPTIMIZED ENGINEERED NUCLEASES HAVING SPECIFICITY FOR THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE External link
Filling date: 8 Sep 2025 Issue date: 22 Apr 2021
Application
Utility: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES External link
Filling date: 8 Sep 2025 Issue date: 25 Feb 2021
Application
Utility: ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE External link
Filling date: 8 Sep 2025 Issue date: 25 Feb 2021
Application
Utility: ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN BETA-2 MICROGLOBULIN GENE External link
Filling date: 8 Sep 2025 Issue date: 4 Feb 2021
Application
Utility: TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES External link
Filling date: 8 Sep 2025 Issue date: 7 Jan 2021
Application
Utility: CO-STIMULATORY DOMAINS FOR USE IN GENETICALLY-MODIFIED CELLS External link
Filling date: 8 Sep 2025 Issue date: 24 Dec 2020
Grant
Utility: Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome External link
Filling date: 8 Sep 2025 Issue date: 1 Dec 2020
Application
Utility: GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR) External link
Filling date: 8 Sep 2025 Issue date: 26 Nov 2020
Application
Utility: NUCLEIC ACID MOLECULES ENCODING AN ENGINEERED ANTIGEN RECEPTOR AND AN INHIBITORY NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOF External link
Filling date: 8 Sep 2025 Issue date: 29 Oct 2020
Grant
Utility: Co-stimulatory domains for use in genetically-modified cells External link
Filling date: 8 Sep 2025 Issue date: 13 Oct 2020
Grant
Utility: Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene External link
Filling date: 8 Sep 2025 Issue date: 13 Oct 2020
Application
Utility: SELF-LIMITING VIRAL VECTORS ENCODING NUCLEASES External link
Filling date: 8 Sep 2025 Issue date: 1 Oct 2020
Application
Utility: ENGINEERED NUCLEASES THAT TARGET HUMAN AND CANINE FACTOR VIII GENES AS A TREATMENT FOR HEMOPHILIA A External link
Filling date: 8 Sep 2025 Issue date: 24 Sep 2020
Grant
Utility: Treatment of retinitis pigmentosa using engineered meganucleases External link
Filling date: 8 Sep 2025 Issue date: 1 Sep 2020
Grant
Utility: Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof External link
Filling date: 8 Sep 2025 Issue date: 18 Aug 2020
Application
Utility: ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE HEPATITIS B VIRUS GENOME External link
Filling date: 8 Sep 2025 Issue date: 30 Jul 2020
Application
Utility: MODIFIED EPIDERMAL GROWTH FACTOR RECEPTOR PEPTIDES FOR USE IN GENETICALLY-MODIFIED CELLS External link
Filling date: 8 Sep 2025 Issue date: 30 Jul 2020
Application
Utility: METHODS FOR REDUCING DNA-INDUCED CYTOTOXICITY AND ENHANCING GENE EDITING IN PRIMARY CELLS External link
Filling date: 8 Sep 2025 Issue date: 18 Jun 2020

Showing 1 to 50 of 64 patents.